Patients switch to lower dose of Pfizer’s RA pill after safety signal
Experts call for lower disease activity threshold for biologic drugs
Drugmaker could file in EU in coming weeks, according to report
AbbVie has reported positive top-line results for its oral JAK1-selective inhibitor in rheumatoid arthritis (RA), bringing it closer to a potential new early treatment option for patients.
Doubts over marketability of drug if it is approved